OmniAb reported a decrease in Q4 revenue to $8.4 million, primarily due to lower license and service revenue, while net loss widened slightly to $14.2 million. Despite the financial decline, the company expanded its partner base to 107 active partners and launched OmniUltra™, a new transgenic chicken technology for antibody discovery.

OmniAb reported a robust first quarter in 2025 with increased revenue driven by milestone payments and higher license fees, alongside a reduced net loss due to lower operating expenses. The company also announced strategic initiatives like the xPloration® Partner Access Program and affirmed its 2025 financial guidance.

OmniAb delivered $10.8 million in Q4 2024 revenue, more than doubling year-over-year, primarily due to higher license and milestone revenue. The company continues to expand its partnerships and clinical-stage programs while maintaining steady operating expenses.

OmniAb reported a decrease in revenue for Q3 2024, primarily due to the timing of milestones and lower ion channel service revenue. Despite the revenue decline, research and development and general and administrative expenses decreased. The company maintains a strong cash position and is focused on sustainable, profitable growth.

OmniAb's second quarter results were in line with expectations, with revenue increasing to $7.6 million compared to $6.9 million in the same period in 2023. The company added new partnerships and programs, and existing partners made clinical progress.

OmniAb reported a decrease in revenue for Q1 2024 to $3.8 million, compared to $16.9 million in the same period in 2023, primarily due to the recognition of a $10 million milestone in 2023 and lower service revenue. The company's net loss increased to $19.0 million, or $0.19 per share, compared to a net loss of $6.1 million, or $0.06 per share, for the same period in 2023.

OmniAb reported a decrease in revenue for the fourth quarter of 2023, primarily due to the recognition of a $25.0 million milestone payment in the prior-year period and lower service revenue. The company signed 10 new licenses in 2023, including three in the fourth quarter.

OmniAb reported a revenue of $5.5 million for Q3 2023, a decrease from $6.9 million in the same period in 2022. The net loss for the quarter was $15.7 million, or $0.16 per share, compared to a net loss of $12.6 million, or $0.15 per share, for the same period in the previous year. The decrease in revenue was primarily driven by lower service revenue, while the increase in net loss was primarily due to higher personnel costs and expenses related to being an independent publicly traded company.

OmniAb reported revenue of $6.9 million for the second quarter of 2023, a slight decrease compared to $7.2 million in the same period in 2022. The company's net loss for the quarter was $14.7 million, or $0.15 per share, compared to a net loss of $10.3 million, or $0.12 per share, for the same period in 2022. The company added four new partners and saw progress in partner programs, with two new programs entering the clinic.

OmniAb reported a strong start to 2023, with revenue increasing to $16.9 million due to a $10.0 million milestone payment. The company reached 301 active programs, with 27 in clinical development or approved for commercialization.

OmniAb reported Q4 2022 revenue of $35.3 million, a significant increase compared to $15.3 million in Q4 2021, driven by a $25.0 million milestone payment from the first commercial sale of TECVAYLI™ in the U.S. Net income for the quarter was $6.8 million, a substantial improvement from the net loss of $3.1 million in the same period last year.

OmniAb reported revenue of $6.9 million for the third quarter of 2022, compared to $6.3 million for the same period in 2021. The net loss for the quarter was $12.6 million, compared to a net loss of $7.9 million in 2021.